Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 43 for “"T cell therapy"”.
-
Enhancing Chimeric Antigen Receptor T cell therapy in Mouse EGFRvIII Heterogeneous Glioblastoma
<p>Chimeric antigen receptor (CAR) T cell therapy for glioblastoma remains challenging due to insufficient CAR T cell abundance and antigen-negative tumor cells evading targeting. Unfortunately, most preclinical studies evaluating CAR T cells in glioblastoma use tumors expressing a single antigen, …
-
Allogeneic Double Negative T cell Therapy as a Novel Treatment for AML Patients
… unmet need for a treatment that can target chemotherapy-resistant blasts with low off-tumor toxicity. Approaches to prevent GvHD while maintaining or enhancing graft-versus-leukemia (GvL) are the ‘Holy Grail’ for allo-BMT patients. CD3+ CD4- CD8- double negative T cell (DNT) is an unconventional …
-
Enhancing efficacy of oncolytic myxoma virus and adoptive T cell therapy against tumors
Immunotherapy in general and adoptive cell transfer in particular have recently been in the spotlight of cancer research. Recent FDA approval of the first immunotherapeutic drugs and promising results in clinical trials suggest that this therapeutic modality holds great promise in fighting cancers. …
-
Multi-Pronged Approach to Understanding the Toxicity Associated with CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has revolutionised cancer immunotherapy, providing effective treatment for previously untreatable malignancies. Its success, in treat ment of haematological cancers, is now fast-advancing to solid tumours. Though, these efforts are faced with many …
-
Evaluation of Adoptive T Cell Therapy and Oncolytic Virotherapy for Treatment of Brain Tumors
Item reinstated by Sarah Shreeves (sshreeve@illinois.edu) on 2013-01-22T11:00:26Z Item was in collections: University of Illinois Dissertations and Theses (ID: 204) Neuroscience Program Dissertations (ID: 630) No. of bitstreams: 3 Thomas_Diana.pdf.txt: 257425 bytes, checksum: …
-
Engineering VHH-based chimeric antigen receptor (CAR) T cell therapy for solid tumor treatment
Chimeric antigen receptor (CAR) T cells are a promising cancer therapeutic, as they can specifically redirect the cytotoxic function of a T cell to a chosen target of interest. CAR T cells have been successful in clinical trials against hematological cancers, but have experienced low efficacy …
-
Leveraging Systems Immunology To Understand The Molecular Underpinnings Of Chimeric Antigen Receptor T-Cell Therapy
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising strategy for the treatment of human cancers, and in the last decade has progressed from breakthrough early trials to first in class FDA approvals for B-cell leukemias and lymphomas. Concurrent with the promise and challenges in cancer …
-
Generation of a novel pan-cancer chemokine receptor-modified CAR-T cell therapy directed towards nfP2X7
CAR-T cell therapy has achieved significant success in the treatment of multiple haematological malignancies. However, solid cancers present challenges such as tumour antigen heterogeneity and complex mechanisms of immune evasion that have limited the translation of CAR-T cell therapies from …
-
Activating The 4-1Bb Pathway For The Expansion of Tumor-Infiltrating Lymphocytes For Adoptive T-Cell Therapy For Metastatic Melanoma Patients
… lymphocytes (TIL) used in Adoptive T-cell therapy by understanding the role of 4-1BB/CD137 co-stimulation during the expansion of the tumor-infiltrating lymphocytes (TIL). Adoptive T-cell therapy using TIL is a promising therapy for late stage melanoma patients, resulting in a 50% …
-
Exploring Veto Activity: DNAM-1-CD155 Axis in Overcoming NK Cell-Mediated Allo-Rejection and Applications for CAR-T Cell Therapy
… Miller et al. defined veto activity, it enables cells to target host cytotoxic T lymphocyte (CTL) precursors specific to veto cells' antigens, selectively eliminating anti- donor T cell clones without inducing rejection. By leveraging this unique immune property, two key research aims were …
-
Utilizing in vivo genome-wide CRISPR/Cas9 screens in immunocompetent mouse models to identify novel tumor liabilities and explore mechanisms of resistance to Chimeric Antigen Receptor T-cell therapy
… in immunocompetent murine models of GBM or B-cell Acute Lymphoblastic Leukemia (B-ALL). Importantly each screen is the first of its kind with no prior genome-wide screens having been conducted in vivo in an immunocompetent murine model of GBM. The 2 screens conducted in GBM sought to better …
-
Mathematical Modelling of Immuno-Oncology and Related Immunology
<p>Immunotherapy offers new and promising treatments for many different types of cancer, but the problem of how to practically regulate the immune response in a way that allows it to fight cancer without overwhelming patients with potentially fatal inflammatory toxicity has yet to be solved. This …
-
Adoptive cell therapy using primary T lymphocytes with genetically engineered T cell receptors against melanoma and glioma
… have shown promising results, including therapy with adoptive cell transfer (ACT) of T lymphocytes. T cell immunotherapy is highly attractive because T cells have the ability to selectively recognize and destroy malignant neoplastic cells. Although a promising approach, one of the …
-
Efficacy of Dual Cd19-Cd79B Car In B-Cell Malignancies
… responses, about 30%-60% of patients with B-cell malignancies relapse following CD19-targeting chimeric antigen receptor (CAR) T cell therapy. CD19 loss is a major cause of relapse and resistance after CD19 CAR T therapy. Dual antigen targeting could overcome resistance due to antigen escape …
-
Characterization and Optimization of Antigen-Specific T Cell Responses During Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes
… of metastatic melanoma with tumor reactive T cells (adoptive T cell therapy, ACT) is a promising approach associated with a high clinical response rate. However, further optimization of this treatment modality is required to increase the clinical response after this therapy. ACT in melanoma …
-
Immunotherapy for murine glioma
Oncolytic viral immunotherapy is a novel approach to cancer treatment. Viruses can directly kill cancer cells, provide antigens to dendritic cells to stimulate a T cell response, and make cancer cells express genes of immune-enhancing cytokines locally within the tumor microenvironment. We …
-
Development of a canine model to evaluate CAR-T cell subsets
Immunotherapy is a rapidly expanding therapeutic modality in the oncology clinic. Immunotherapy with chimeric antigen receptor (CAR) T cells has demonstrated success in human blood cancers, although relapse occurs in ~50% of patients. In the context of solid tumors, CAR-T cells show only transient …
-
BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia
B-cell acute lymphoblastic leukemia is the most common pediatric cancer, responsible for the most cancer-related deaths in children. Advances in chemotherapy over the past half-century have steadily increased the remission and survival of children with B-cell acute lymphoblastic leukemia to nearly …
-
The Characterization of T-Cell Manufacturing For Adoptive T-Cell Therapies
<p>Adoptive T-cell therapy using genetically modified T cells has emerged as a potential therapeutic option for several malignancies. Central to the production of the cellular therapy is the manufacturing using a stimulation, genetic engineering, and expansion methodology. Within this framework, …
-
Efficacy and Mechanism of Â-Defensin2 Fused Antigen Protein Vaccines
… release levels by antigen specific effector T cells when antigen is crosspresented by dendritic cells (DC) which absorbed mBD2 vaccine (mBD2 fused antigen protein) over antigen alone. We move unto an in vivo model and note significant increases in the expansion of antigen specific class I T …
Page 1 of 3